Long-term Outcomes of Breast Cancer Patients After Wound Infiltration Analgesia

• Status: Completed
• Trial end date: 2023-04-05
• Target enrollment: 0
• Participant gender: Female

Summary

In the study that was conducted from 05.01.2009 - 31.12.2012. 120 patients were examined. By drawing random numbers, the patients were randomized into 3 groups for postoperative analgesia:

1. Diclofenac 2 mg/kg/day - control,

2. Wound infiltration via wound catheter with catheter tip placed in the axilla, 3*0.5 mg/kg 0.5% levobupivacaine bolus dose.

3. 0.05 mg/kg/h 0.5% levobupivacaine continuously via wound infiltration catheter with catheter tip placed in the axilla. The drug was delivered using a PCA pump for 24 hours.

The aim was to compare early postoperative outcomes - pain control on a visual analog scale of 1-10, hand grip strength, and quality of life after surgery and after 1 year.

Long-term survival was examined subsequently, from the hospital register.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Osijek University Hospital
• Treatments: Levobupivacaine

Criteria

Inclusion Criteria: Breast cancer patients aged 30 - 75 who consented to participate in the study and whose disease requires axillary lymph node dissection.

-

Exclusion Criteria: aged <30 years - >75 years, who did not consent to participate in the study. Patients who after histological analysis did not require axillary lymph node dissection, with known intolerance to study drugs, and who unintentionally removed wound infiltration catheters.

-